News & Events
News & Events
Green light for development of first in class hepatitis C drug
2016-11-01
IPK licenses out a hepatitis C virus drug candidate to J2H Biotech
In 2013, Institut Pasteur Korea identified a Thiophene Urea (TU) compound series. TU inhibits HCV’s ability to enter into hepatocytes by targeting a viral protein, and it prevents cell-to-cell spread of the virus, thereby inhibiting the major route of HCV transmission in the liver. After final optimization was complete, on Oct. 2016, the first-in-class HCV drug candidate was out-licensed to J2H.
JaeSun Kim, Co-CEO, J2H, says, "IPK's HCV entry inhibitor will be an alternative way of satisfying the needs of many. And I expect there will be synergy in combining it with HCV protease inhibitors.“
Dr. Marc Windisch, Group Head, IPK Hepatitis Research Laboratory, says, “TU is ideal to prevent reinfection of graft in patients undergoing liver transplantation.”
Source: Kiho Ilbo (November 1, 2016)
In 2013, Institut Pasteur Korea identified a Thiophene Urea (TU) compound series. TU inhibits HCV’s ability to enter into hepatocytes by targeting a viral protein, and it prevents cell-to-cell spread of the virus, thereby inhibiting the major route of HCV transmission in the liver. After final optimization was complete, on Oct. 2016, the first-in-class HCV drug candidate was out-licensed to J2H.
JaeSun Kim, Co-CEO, J2H, says, "IPK's HCV entry inhibitor will be an alternative way of satisfying the needs of many. And I expect there will be synergy in combining it with HCV protease inhibitors.“
Dr. Marc Windisch, Group Head, IPK Hepatitis Research Laboratory, says, “TU is ideal to prevent reinfection of graft in patients undergoing liver transplantation.”
Source: Kiho Ilbo (November 1, 2016)